SMELLPARK: Role of Nasal Dysbiosis in Parkinson Disease

Sponsor

Institut Pasteur (Industry)

Overall Status

Recruiting

CT.gov ID

NCT04249245

Collaborator

(none)

320

Enrollment

Locations

41.9

Anticipated Duration (Months)

160

Patients Per Site

3.8

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Condition or Disease	Intervention/Treatment	Phase
Parkinson Disease	Other: Nasal Swab

Detailed Description

Olfactory dysfunction is frequent in Parkinson Disease (PD) and may be present years before the motor symptoms appear. The early olfactory dysfunction could result from environmental factors acting through the nasal cavity such as microbial communities. Local inflammation induced by a nasal bacterial dysbiosis (microbiota imbalance) could lead to early neuronal dysfunctions in the olfactory system propagating in all the brain, thus inducing motor, cognitive and emotional manifestations in PD, in keeping with the Braak's stage hypothesis. We propose a translational project aiming at investigating the potential influence of nasal dysbiosis in PD pathogenesis. First, we will analyze both olfaction and nasal microbiota in a large series of PD patients and test the link between olfactory deficits and nasal dysbiosis. Then, we will take advantage of studying two populations of subjects with a very different environmental exposure (in mainland France and French West Indies) to isolate the abnormalities of the nasal microbiota that could be specific for PD. The study will be performed in 160 patients and 160 healthy volunteers. Patients will be enrolled in two investigators sites of which different environmental exposure: 1) Guadeloupe Hospital, French West Indies and 2) Pitie-Salpetriere Hospital, Paris, France. The patient selection will be conducted in consultation with the physician and it will be proposed to the spouse to participate as controls. The study subjects will be enrolled after collecting their informed consent.

As soon as the study subjects are included, the following measurements will be done at once at the inclusion:

Neurological assessment: Idiopathic PD. Severity of the disease will be evaluated using the Hoehn and Yahr staging. Non-motor manifestations of the disease will be assessed using the Non-Motor Symptoms Scale (NMSS). Severity of REM behavior disorder will be evaluated using the Innsbruck REM sleep behaviour disorder inventory .
Olfactory function: Olfactory performance will be measured using (a) the Sniffin' Stick test battery (Burghardt, Wedel, Germany) following a standardized procedure and (b) a discrimination test of odorant mixtures developed by the Research Unit.
Global cognitive performance and executive functions: The Montreal Cognitive Assessment (MoCA) will be used to assess global cognitive performance. Frontal Assessment Battery (FAB) will be used to detect executive dysfunction.
Memory: The delayed paragraph recall index from the Wechsler Memory Scale IV-Revised will be employed as a valid, sensitive measure of verbal declarative memory and a surrogate marker of hippocampal function.
Mood disorders: Two self-questionnaires will be used: the Snaith-Hamilton pleasure scale to assess anhedonia severity, and the Quick inventory of depressive symptomatology-self-rated for depression intensity evaluation. Two clinician rating tests for depression severity will also be used: the Hamilton Depression Rating Scale 17 and the MINI.

Sampling of human microbiota will be performed at the end. Subjects will undergo nasal brushing from anterior nares after local epinephrine application with a sterile flocked swab inserted and gently rolled around the inside of both nostrils. Swabs (one per nostril) will be placed on ice immediately after collection and then frozen at -80°C before shipment to the

Research Unit (Institut Pasteur) where analyses will be carried out:

Immunohistochemistry analysis: The levels of Neuroinflammation and aSyn proteins will be analyzed in the nasal tissue samples.
Microbiome analysis: Microbial composition will be determined by metagenomic (pan-bacterial 16S rRNA gene sequencing).

Study Design

Study Type:

Observational

Anticipated Enrollment :

320 participants

Observational Model:

Case-Control

Time Perspective:

Cross-Sectional

Official Title:

Role of Nasal Dysbiosis in Parkinson Disease

Actual Study Start Date :

Feb 14, 2020

Anticipated Primary Completion Date :

Aug 13, 2023

Anticipated Study Completion Date :

Aug 13, 2023

Arms and Interventions

Arm	Intervention/Treatment
Parkinson Patients These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris). They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015.	Other: Nasal Swab All
Control Subjects They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned. If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group.	Other: Nasal Swab All

Arm

Intervention/Treatment

Parkinson Patients

These patients are Hospitalized or consult in the participating hospitals of the Pointe à Pitre (Guadeloupe), or at the Pitié-Salpêtrière hospital (Paris). They were diagnosed Idiopathic PD (Parkinson Disease). The diagnosis is made according to the MDS criteria described in Postuma and al. 2015.

Other: Nasal Swab

All

Control Subjects

They are Spouse of Parkinson Patients group , with an age difference <5 years compared to the patient concerned. If the Spouse can't be included, a corresponding control subject could be recruited in the consultation with an age difference <5 years compared to the patient concerned, in respecting the final gender ratio of the PD group.

Other: Nasal Swab

All

Outcome Measures

Primary Outcome Measures

Bacterial composition of the nasal swab samples based on 16S sequencing of DNA [3 years]
The operational taxonomic units (OTU) will be constructed and comparison between groups will be performed.

Secondary Outcome Measures

Epidemiological characteristics of patients PD [3 years]
Demographic variables (locations of residence and types of housing), risk factors (activities, diet, history family).
Olfactory function [3 years]
Olfactory performance will be measured using the Sniffin' Stick test battery (Burghardt, Wedel, Germany) following a standardized procedure and a discrimination test of odorant mixtures developed by the Research Unit
Neurological assessment: Idiopathic PD - Hoehn and Yahr staging. [3 years]
Severity of the disease will be evaluated using the Hoehn and Yahr staging.
Neurological assessment: Idiopathic PD - Non-Motor Symptoms Scale (NMSS) [3 years]
Severity of non-motor manifestations of the disease will be assessed using the Non-Motor Symptoms Scale (NMSS).
Neurological assessment: Idiopathic PD - the Innsbruck REM sleep behaviour disorder inventory [3 years]
Severity of REM behavior disorder will be evaluated using the Innsbruck REM sleep behaviour disorder inventory .
Global cognitive performance - MoCA [3 years]
The Montreal Cognitive Assessment (MoCA) will be used to assess global cognitive performance.
Executive functions [3 years]
Frontal Assessment Battery (FAB) will be used to detect executive dysfunction.
Memory Function [3 years]
The delayed paragraph recall index from the Wechsler Memory Scale IV-Revised will be employed as a valid, sensitive measure of verbal declarative memory and a surrogate marker of hippocampal function.
Mood disorders - the Snaith-Hamilton pleasure scale [3 years]
The Snaith-Hamilton pleasure scale (self-questionnaire) will be used to assess anhedonia severity,
Mood disorders - the Quick inventory of depressive symptomatology-self-rated [3 years]
The Quick inventory of depressive symptomatology-self-rated will be used for depression intensity evaluation.
Mood disorders - the Hamilton Depression Rating Scale 17 [3 years]
The Hamilton Depression Rating Scale 17, a clinician rating test, will also be used to assess depression severity.
Mood disorders - the MINI [3 years]
The MINI, a clinician rating test, will also be used to assess depression severity.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Patients (PD)

Age > 18 years
Idiopathic PD
In Guadeloupe (N=80) : living for more than 15 years in Caribbean, including the 5 first years.
In Paris (N=80): living for more than 15 years in mainland France, including the 5 first years.

Controls

Age > 18 years
Spouse of enrolled PD patient or matched controls, with age difference between spouses <5 years. When the spouse cannot be included, a matched control respecting the PD group's final sex ratio and with an age difference <5 years relative to the concerned PD case will be enrolled.

Exclusion Criteria (both PD patients and controls)

Presence of a cold or acute pathology which could explain an original olfactory disorder other than Parkinson's disease
Use of nasal antiseptics within the last 3 months
Refusal of or contraindication to nasal microbiota sampling